AbbVie Inc. (ABBV) Stock

Healthcare · Drug Manufacturers - General · Member of S&P 500

AbbVie Inc. (ABBV) closed at USD 281.75 on 2026-10-14, a change of +27.5 % over the past year, with a market capitalization of USD 500.8B.

AbbVie Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

AbbVie Inc. key figures

Previous close

USD 281.75 (2026-10-14)

1-year change

+27.5 %

Market cap

USD 500.8B

Enterprise value

USD 565.16B

P/E ratio (trailing)

80.06

P/E ratio (forward)

17.48

EPS (trailing)

3.54

EPS (forward)

16.22

PEG ratio

0.58

Price to book

-84.37

Revenue growth

10.2 %

Earnings growth

290.4 %

Dividend per share (trailing)

6.83

Short ratio

3.93

Employees

57,000

Analyst consensus (third-party)

buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About AbbVie Inc.

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for AbbVie Inc. and compare it with other stocks.